Jakavi 15mg Tablet

Visão geral do produto

About Jakavi

Jakavi is a medication containing the active ingredient Ruxolitinib, classified as Medication. Ruxolitinib is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Ruxolitinib, the active ingredient in Jakavi, belongs to the Medication class. 1 INDICATIONS AND USAGE OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Jakavi. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Jakavi for extended periods without medical advice.